Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults

6Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: This open-label, multicenter, single-dose study characterized the pharmacokinetics and short-term safety of azilsartan medoxomil (AZL-M) in hypertensive pediatric subjects (12-16 years [cohort 1a; n = 9]; 6-11 years [cohort 2; n = 8]; 4-5 years [cohort 3; n = 3]). Methods: Model-based simulations were performed to guide dosing, especially in 1-5-year olds, who were difficult to enroll. AZL-M was dosed according to body weight (20-60-mg tablet, cohorts 1a and 2; 0.66 mg/kg granule suspension, cohort 3). In cohort 1, gender-matched healthy adults (cohort 1b; n = 9) received AZL-M 80 mg. Results: Exposure to AZL (active moiety of AZL-M), measured by dose-/body weight-normalized C max and AUC0-∞, was ∼15-30 % lower in pediatric subjects versus adults. In simulations, exposure with 0.66 mg/kg AZL-M in pediatric subjects weighing 8-25 kg approximated to AZL-M 40 mg (typical starting dose) in adults. The simulations suggest that 25-50-kg subjects require half the adult dose (10-40 mg), whereas 50-100-kg subjects can use the same dosing as adults. Adverse events were mild in intensity, apart from one moderate event (migraine). Conclusions: This dosing strategy should be safe in pediatric patients, as AZL exposure would not exceed that seen in adults with the highest approved AZL-M dose (80 mg).

References Powered by Scopus

The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents

6175Citations
N/AReaders
Get full text

New equations to estimate GFR in children with CKD

2942Citations
N/AReaders
Get full text

Mechanism-based concepts of size and maturity in pharmacokinetics

910Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Formulation and evaluation of solid self-microemulsifying drug delivery system for azilsartan medoxomil

11Citations
N/AReaders
Get full text

Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments

5Citations
N/AReaders
Get full text

Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study

4Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Webb, N. J. A., Wells, T., Tsai, M., Zhao, Z., Juhasz, A., & Dudkowski, C. (2016). Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults. European Journal of Clinical Pharmacology, 72(4), 447–457. https://doi.org/10.1007/s00228-015-1987-8

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 21

81%

Researcher 3

12%

Professor / Associate Prof. 1

4%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

52%

Pharmacology, Toxicology and Pharmaceut... 6

24%

Nursing and Health Professions 4

16%

Psychology 2

8%

Save time finding and organizing research with Mendeley

Sign up for free